Pulse Biosciences, Inc. (PLSE)

NCM – Real Time Price. Currency in USD

23.30

+4.22 (22.12%)

At close: May 12, 2026, 4:00 PM EDT

23.15

-0.15 (-0.64%)

Pre-market: May 13, 2026, 7:56 AM EDT

12.05.2026

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences' common stock through its at-the-market equity offering program (ATM) during the Company's designated trading window. In total, the Co-Chairmen acquired 675,233 shares of Pulse Bi.

08.05.2026

Pulse Biosciences Q1 Earnings Call Highlights

Pulse Biosciences NASDAQ: PLSE said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new clinical data from its cardiac catheter program.

08.05.2026

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, NV. Pulse Biosciences' Management is scheduled to present on Wednesday, May 13, at 4:35 pm PT. A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of the.

08.05.2026

Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript

07.05.2026

Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?

Pulse Biosciences (PLSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

04.05.2026

Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates

Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.17 per share a year ago.

04.05.2026

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the first quarter ended March 31, 2026. Recent Business Highlights Endocardial Catheter AF Ablation Announced strategic prioritization of the nPulse Cardiac Catheter System following landmark clinical data, presented at AF Symposium, demonst.

Videos

No Data

There is no data to display

Press releases

12.05.2026

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

04.05.2026

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

25.04.2026

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking positive clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting. The late-breaking presentation included incremental participant follow up data. Building upon the previously reported data set presented at.

20.04.2026

Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its nPulse™ Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois. At HRS 2026, Pulse Biosciences will present late‑breaking clinical trial updates, highlighting European feasibility study one‑year outcomes.

Pulse Biosciences, Inc. (PLSE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Pulse Biosciences, Inc. (PLSE)

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Q1 Earnings Call Highlights

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript

Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?

Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Videos

No Data

Press releases

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Q1 Earnings Call Highlights

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript

Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?

Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Videos

No Data

Press releases

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

Search stocks

Pulse Biosciences, Inc. (PLSE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Pulse Biosciences, Inc. (PLSE)

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Q1 Earnings Call Highlights

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript

Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?

Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Videos

No Data

Press releases

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Q1 Earnings Call Highlights

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript

Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?

Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Videos

No Data

Press releases

ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting